Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model

Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), used for the treatment of advanced or metastatic non-small cell lung cancer. Recently, studies proved that Gefitinib-induced cardiotoxicity through induction of oxidative stress leads to cardiac hypertroph...

Descripción completa

Detalles Bibliográficos
Autores principales: Alanazi, Wael A., Alhamami, Hussain N., Alharbi, Metab, Alhazzani, Khalid, Alanazi, Abdulrahman S., Alsanea, Sary, Ali, Nemat, Alasmari, Abdullah F., Alanazi, Ahmed Z., Alotaibi, Moureq R., Alswayyed, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508643/
https://www.ncbi.nlm.nih.gov/pubmed/36164571
http://dx.doi.org/10.1016/j.jsps.2022.06.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508643/
https://www.ncbi.nlm.nih.gov/pubmed/36164571
http://dx.doi.org/10.1016/j.jsps.2022.06.020

Ejemplares similares